LYKALABS vs THEMISMED: Stock Comparison

LYKALABS vs THEMIS MEDICAREUpdated 1 Jul 26, 4:08 PM ISTNSE & company filings

THEMIS MEDICARE is the larger company by market capitalisation. LYKALABS shows a lower P/E, while THEMIS MEDICARE shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

LYKALABS leads 2; THEMISMED leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

LYKALABSTHEMISMED

Valuation lens

What price are you paying?

Market CapContext only
₹298 Cr
₹1,187 Cr
P/E RatioLYKALABS has the lower reading
0x
30.51x
P/B RatioLYKALABS has the lower reading
2.67x
3.06x
EPSTHEMISMED has the higher reading
₹0.58
₹3.12
Book ValueContext only
₹25.12
₹43.28
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
THEMISMED is the larger company
₹1,187 Cr vs ₹298 Cr
P/E Ratio
LYKALABS has a lower P/E
0x vs 30.51x
P/B Ratio
LYKALABS has a lower P/B
2.67x vs 3.06x
EPS
THEMISMED has higher earnings per share
₹3.12 vs ₹0.58
Revenue Growth (TTM YoY)
THEMISMED has faster revenue growth
6.7% vs 0%
Qtr Profit Growth
THEMISMED has stronger quarterly profit growth
16.76% vs 2.62%
ROE
THEMISMED has a higher ROE
-4.71% vs -11.49%
ROCE
THEMISMED has a higher ROCE
-0.63% vs -6.25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLYKALABSTHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLYKALABSTHEMISMED
Live Price₹74.83₹128.25
Day Change1.19%-2.89%
Volume88,5561.11 L
52-Week High₹101.9₹148
52-Week Low₹44.1₹64.95
Distance from 52W High-26.57%-13.34%

Valuation

MetricLYKALABSTHEMISMED
Market Cap₹298 Cr₹1,187 Cr
P/E Ratio0x30.51x
P/B Ratio2.67x3.06x
EPS₹0.58₹3.12
Book Value₹25.12₹43.28
Dividend Yield0%0%

Growth

MetricLYKALABSTHEMISMED
Revenue Growth (TTM YoY)0%6.7%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%0%
Qtr Profit Growth2.62%16.76%

Profitability & Leverage

MetricLYKALABSTHEMISMED
ROE-11.49%-4.71%
ROCE-6.25%-0.63%
Net Margin-7.81%0.33%
Operating Margin-6.71%-0.79%
Debt to Equity0.53x0.33x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricLYKALABSTHEMISMED
Promoter Holding58.45% 0.29 pp57.5%
FII Holding0.17% 0.12 pp0.01% 0.1 pp
DII Holding0.66% 0.01 pp0.01%
Public Holding40.72% 0.16 pp32.87% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LYKALABS and THEMIS MEDICARE.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.